TRVN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
Dagens volum	42 532.00
Gjennomsnittsvolum	204 957
Markedsverdi	7.42M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.370 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (2.39%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.75
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

Volum Korrelasjon

Lang: -0.20 (neutral)

Kort: -0.88 (strong negative)

Signal:(52.298) Neutral

Trevena Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Trevena Inc Korrelasjon - Valuta/Råvare

-0.23
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.32
( neutral )

Trevena Inc Økonomi

Annual	2023
Omsetning:	$3.13M
Bruttogevinst:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2023
Omsetning:	$3.13M
Bruttogevinst:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2022
Omsetning:	$-418 000
Bruttogevinst:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
Omsetning:	$567.00
Bruttogevinst:	$-387.00 (-68.25 %)
EPS:	$-0.0101

Financial Reports:

No articles found.

Trevena Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Sanntidsoppdatering for Trevena Inc [TRVN]

Upcoming Earnings Alert

Trevena Inc Options Data

Calls

Puts